Base-case lifetime cost-effectiveness analysis
| Strategy | Total | Incremental vs conventional therapy | Fully incremental | |||||
| QALYs | Costs (£) | QALYs | Costs (£) | ICER | QALYs | Costs (£) | ICER | |
| TNFi-naïve subgroup | ||||||||
| Conventional | 8.991 | £132 349 | N/A | N/A | N/A | N/A | N/A | – |
| Adalimumab | 9.191 | £138 534 | 0.200 | £6185 | £30 982 | Extendedly dominated | ||
| Golimumab | 9.286 | £141 360 | 0.294 | £9012 | £30 602 | Extendedly dominated | ||
| Infliximab | 9.346 | £145 660 | 0.355 | £13 311 | £37 495 | Dominated | ||
| Vedolizumab | 9.462 | £152 694 | 0.471 | £20 345 | £43 205 | Dominated | ||
| Tofacitinib | 9.536 | £143 963 | 0.544 | £11 615 | £21 388 | 0.544 | £11 615 | £21 338 |
| TNFi-exposed subgroup | ||||||||
| Conventional | 8.903 | £132 712 | N/A | N/A | N/A | N/A | N/A | – |
| Adalimumab | 9.051 | £137 035 | 0.148 | £4324 | £29 284 | Extendedly dominated | ||
| Infliximab | 9.051 | £140 661 | 0.148* | £7949 | £53 831 | Dominated | ||
| Golimumab | 9.051 | £138 088 | 0.148* | £5376 | £36 403 | Extendedly dominated | ||
| Vedolizumab | 9.146 | £145 380 | 0.242 | £12 668 | £52 275 | Dominated | ||
| Tofacitinib | 9.240 | £140 399 | 0.337 | £7687 | £22 816 | 0.337 | £7132 | £22 816 |
| Scenario analysis: Overall ITT population† | ||||||||
| Conventional | 8.948 | £132 508 | N/A | N/A | N/A | N/A | N/A | – |
| Vedolizumab | 9.301 | £147 822 | 0.352 | £15 314 | £43 485 | Dominated | ||
| Tofacitinib | 9.397 | £141 500 | 0.449 | £8991 | £20 038 | 0.449 | £8991 | £20 038 |
*In the absence of evidence for golimumab or infliximab in the TNFi-exposed population, a class-effect was assumed and adalimumab values were used.
†NMA results are presented in the supplement.
ICER, incremental cost-effectiveness ratio; ITT, intention-to-treat; NA, not applicable; QALY, quality-adjusted life year; TNFi, tumour necrosis factor inhibitor; TOF, tofacitinib.